Eleusis evaluates potential of LSD in treating Alzheimer’s Disease
Category: #health  By Mateen Dalal  Date: 2019-12-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Eleusis evaluates potential of LSD in treating Alzheimer’s Disease

A clinal stage life science company, Eleusis recently announced results from the Phase 1 clinical trial of LSD (Lysergic Acid Diethylamide), demonstrating the potential of the orally administered low doses of the drug for the treatment of Alzheimer’s disease.

The study demonstrates positive data on the pharmacokinetics, pharmacodynamics, tolerability and safety in healthy-older volunteers over a period of 3 weeks. In the past, LSD has shown clinically relevant therapeutic effects in patients afflicted by substance abuse, depression and anxiety. Prior research also suggests that a low dose LSD may have considerable potential in treating Alzheimer’s disease. This trial conducted by Eleusis was the first registered modern clinical trial on low doses of LSD.

Neiloufar Family, Director of Research at Eleusis and the lead investigator in the study was reportedly quoted saying that they are encouraged by the study results as it provides reassuring safety data and that the frequency of adverse events associated with Lysergic Acid Diethylamide is similar to placebo.

Charles Nichols, Professor of Pharmacology at Louisiana State University and co-author of the study was reported to state that this research with serotonin receptor agonists like LSD, represent a new strategy to treat diseases associated with chronic inflammation.

The unique polypharmacology of LSD may serve to enhance its capacity to regulate several key pathological processes in the brain that are associated with Alzheimer’s disease, along with the neuroinflammation, that are implicated in its progression from mild cognitive impairment.

Shlomi Raz, Chairman & Founder, Eleusis. Stated that the company is exhilarated to share the results of the groundbreaking trial of LSD and consider that this study will serve as the foundation for the promising therapeutic development of Lysergic Acid Diethylamide drug and other psychedelic drugs as therapeutics. Raz added that they are looking forward to unravelling the therapeutic potential of psychedelics at non-psychoactive, subperceptual, doses, to safely address the most urgent unmet needs in public health.

Source Credit: https://www.eleusisltd.com/news/2019/12/18/eleusis-announces-phase-1-trial-results-of-lysergic-acid-diethylamide-lsd-in-healthy-older-volunteers-potential-to-evaluate-as-disease-modifying-therapy-for-alzheimers-disease

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...